NRx Pharmaceuticals Inc(NRXPW)는 NASDAQ에 상장된 기업입니다. 현재가 $0.00 (+0.00%), 시가총액 $714.61M.
NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder (PTSD), and schizophrenia in the United States. It operates through NRx and Dura segments. The company develops NRX-101, an oral fixed-dose combination of D-cycloserine (DCS) and lurasidone in Phase 2/3 clinical testing for bipolar depression with sub-acute ideation and behavior; NRX-100, a preservative-free formulation of ketamine for intravenous infusion and for the treatment of suicidal depression; and KETAFREE, a generic preservative-free formulation of ketamine.
NRx Pharmaceuticals Inc의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 XTS에서 실시간으로 확인할 수 있습니다.
NRx Pharmaceuticals Inc의 현재 주가는 $0.00 (+0.00%)입니다. XTS에서 실시간 시세와 차트를 확인할 수 있습니다.
NRx Pharmaceuticals Inc의 시가총액은 약 $714.61M입니다.
NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic…